About Us

Our mission: to help people living with Parkinson’s to live well today.


Support Us

News in Context: Second Phase 2 Trial of CERE-120 Yields Disappointing Results


Ceregene today announced disappointing results from its second Phase 2 trial of CERE-120, an experimental gene therapy treatment for Parkinson’s disease (PD). CERE-120 was designed to deliver neurturin, a specialized protein known as a trophic factor, into the brain. The hope was that it might heal diseased brain cells, helping to slow the progression of the disease, a therapeutic effect suggested in pre-clinical studies of neurturin.

CERE-120 did not reach its primary endpoint in this study, unfortunate news which makes it unclear if it will remain in development. Still, there is a lot to be learned from Ceregene’s research that could have important implications for developing similar trophic factor therapies for PD moving forward. Read more here.

This entry was posted in News. Bookmark the permalink.